The findings of a new study lend support for type 1 diabetes autoantibody screening in people with other autoimmune conditions to prevent complications such as diabetic ketoacidosis.
People with celiac disease, hyperthyroidism or hypothyroidism have a three-fold increase in the risk of developing type 1 diabetes, according to a recent study published in Diabetes, Obesity and Metabolism.
Steve V. Edelman, M.D.
Researchers, led by Steve V. Edelman, M.D., an endocrinologist and professor of medicine at UC San Diego Health, wanted to investigate the link between type 1 diabetes (T1D) and the presence of other autoimmune conditions. Specifically, they wanted to determine whether people with celiac disease, hyperthyroidism, or hypothyroidism have an elevated risk of developing type 1 diabetes.
Type 1 diabetes is characterized by autoimmune destruction of pancreatic beta cells, leading to insulin deficiency. It often coexists with other autoimmune disorders.
For example, celiac disease and type 1 diabetes are both linked to human leukocyte antigen (HLA), which are genes that code for proteins and play an important role in the immune system. Approximately 95% of people with type 1 diabetes and almost 99% of those with celiac disease carry the HLA class II genes DQ2 and DQ8, according to Breakthrough T1D. However, most people with these genes do not develop type 1 diabetes or celiac disease.
The analysis published in Diabetes, Obesity and Metabolism was a retrospective, observational study. Researchers used the Optum Clinformatics claims database for claims from Jan. 1, 2017, to Sept. 30, 2023. The Optum Clinformatics database contains real-world data in the form of health claims for approximately 17 million to 19 million members of large commercial and Medicare Advantage health plans, as well as data from claims submitted for medical and pharmacy healthcare services.
Included in this analysis were patients with a diagnosis of celiac disease (47,099), hyperthyroidism (164,830) and hypothyroidism (980,477) and an equal number of matched controls.
Researchers found that the risk of developing type 1 diabetes was significantly higher in people with these conditions compared with matched controls. The increased risk was observed in both children and adults, and even in people without a family history of type 1 diabetes. In total, 0.14% of those with celiac disease developed type 1 diabetes compared with 0.06% of controls. Similarly, 0.17% of those with hyperthyroidism developed type 1 diabetes compared with 0.06% of controls. In the hypothyroidism cohort, 0.18% of participants developed type 1 diabetes compared with 0.08% of controls.
Subgroup and sensitivity analyses generally supported the main findings, although the risk associated with newly diagnosed hypothyroidism was lower. A secondary analysis that defined type 1 diabetes using both diagnosis and insulin use showed a higher risk in those with celiac disease and hyperthyroidism, but not with hypothyroidism.
The findings align with existing literature that indicates a genetic and immunological link between autoimmune diseases. More than half of new type 1 diabetes cases occur in adults, highlighting the relevance of screening beyond childhood.
Early detection of type 1 diabetes through autoantibody screening — particularly in people with other autoimmune conditions — could prevent complications such as diabetic ketoacidosis, a serious complication of diabetes. Without enough insulin, cells are not able to use sugar for energy. The liver will begin to break down fat for fuel, which produces acids called ketones.
Related: Adults Should be Part of Early Screening Efforts for Type 1 Diabetes
Researchers said the limitations of the study include reliance on ICD-10-CM codes, potential misclassification of diagnoses, incomplete medical histories due to insurance data gaps, and a relatively short follow-up period. Additionally, the autoimmune origin of thyroid conditions in the dataset could not be specifically confirmed. Despite these constraints, the study provides evidence that supports routine screening for type 1 autoantibodies in individuals with coexisting autoimmune diseases, regardless of age or family history.
Adult-Onset Type 1 Diabetes Increases Risk of Cardiovascular Disease
June 2nd 2025The risk of major cardiac events was 50% higher in adult-onset type 1 diabetes than in population controls, and the risk of death from diabetic coma or ketoacidosis was seven times as high as those with type 2 diabetes.
Read More
World’s First Immunotherapy Trial for Type 1 Diabetes Is Underway in Australia
May 23rd 2025Led by the University of Queensland’s research facility, Frazer Institute, the trial examining the drug ASITI-201 is the first of its kind in the world and has already dosed its first five participants.
Read More
Breakthrough T1D Awards $2.8 Million for New Center of Excellence
May 1st 2025The new research center at the University of Michigan and Oregon Health & Science University intends to develop a clinical trial platform that will be used to test several heart and kidney therapies in people living with type 1 diabetes.
Read More
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More